MARCHESELLI, Raffaella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.213
EU - Europa 2.236
AS - Asia 717
OC - Oceania 10
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 2
Totale 7.190
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.180
GB - Regno Unito 1.180
IT - Italia 296
CN - Cina 279
SE - Svezia 207
SG - Singapore 170
DE - Germania 163
HK - Hong Kong 122
UA - Ucraina 98
FR - Francia 96
FI - Finlandia 70
TR - Turchia 63
BG - Bulgaria 41
IN - India 31
CA - Canada 21
ID - Indonesia 18
BE - Belgio 17
IE - Irlanda 12
RU - Federazione Russa 12
AU - Australia 10
VN - Vietnam 10
CH - Svizzera 8
CZ - Repubblica Ceca 8
IR - Iran 7
MY - Malesia 7
LT - Lituania 6
NL - Olanda 6
BZ - Belize 5
BR - Brasile 4
ES - Italia 4
AT - Austria 3
EU - Europa 3
GP - Guadalupe 3
KR - Corea 3
MX - Messico 3
CL - Cile 2
DK - Danimarca 2
HU - Ungheria 2
LB - Libano 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BH - Bahrain 1
CR - Costa Rica 1
EC - Ecuador 1
IL - Israele 1
JP - Giappone 1
KZ - Kazakistan 1
MA - Marocco 1
MM - Myanmar 1
MU - Mauritius 1
PE - Perù 1
PL - Polonia 1
PT - Portogallo 1
RS - Serbia 1
Totale 7.190
Salva come PNG Salva come JPEG
Città #
Southend 1.070
Fairfield 592
Woodbridge 458
Ashburn 356
Chandler 269
Houston 266
Seattle 240
Wilmington 216
Ann Arbor 206
Cambridge 205
Santa Clara 205
Jacksonville 202
Dearborn 163
Nyköping 162
Beijing 129
Singapore 129
Hong Kong 122
Modena 94
New York 76
San Diego 57
Frankfurt am Main 42
Princeton 42
Sofia 41
Eugene 38
Helsinki 36
Izmir 29
Bremen 26
London 26
Milan 23
Bologna 22
Brussels 17
Redwood City 17
Falls Church 16
Nanjing 13
Boardman 12
Des Moines 12
Dublin 12
Fremont 12
Jakarta 12
San Jose 12
Shanghai 12
Dong Ket 10
Rome 10
New Delhi 9
Norwalk 9
Rho 9
Chicago 8
Hefei 8
Indiana 8
Kunming 8
Ottawa 8
Phoenix 8
San Giuliano Milanese 8
San Mateo 8
Gurugram 7
Uppsala 7
Dongguan 6
Hebei 6
Verona 6
Belize City 5
Melbourne 5
Padova 5
Reggio Emilia 5
Stockholm 5
Toronto 5
Turin 5
Ardabil 4
Augusta 4
Carpi 4
Guangzhou 4
Hounslow 4
Kilburn 4
Lille 4
Mirandola 4
Novate Milanese 4
Paris 4
Parma 4
Saint Petersburg 4
Stoneham 4
Zhengzhou 4
Abano Terme 3
Amritsar 3
Auburn Hills 3
Brno 3
Gainesville 3
Jinan 3
Lavello 3
Leawood 3
Nanchang 3
Palangkaraya 3
Roncoferraro 3
Saint-Francois 3
Sydney 3
Bangalore 2
Banjarmasin 2
Baotou 2
Beachwood 2
Budapest 2
Castelnuovo Rangone 2
Catanzaro 2
Totale 5.976
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 523
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 321
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 259
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 254
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 252
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 251
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 208
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 208
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. 204
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 203
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 197
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 195
A concise review of lenalidomide therapy for follicular lymphoma 194
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 191
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 187
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 181
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 180
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy 178
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 175
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 170
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 163
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 163
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 156
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 153
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 153
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 151
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 148
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 148
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 145
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. 145
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 145
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 141
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 136
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 130
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 126
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 117
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 109
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 106
Epidemiologia degli infortuni lavorativi in minori: risultati di una indagine condotta nella città di Modena nel periodo gennaio-giugno 2000. 101
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 96
Totale 7.263
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.287
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.287
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.142 0 0 0 0 147 207 212 158 160 65 92 101
2020/20211.437 186 62 110 150 197 94 81 122 67 114 176 78
2021/2022874 30 86 80 49 24 74 49 50 107 61 156 108
2022/2023854 92 111 60 78 98 118 26 87 93 10 55 26
2023/2024683 24 26 49 63 145 59 146 48 17 16 35 55
2024/2025487 66 19 42 121 239 0 0 0 0 0 0 0
Totale 7.263